Sunday, June 11, 2017 8:22:43 AM
The main difference between the two is that Indoximod is mainly a IDO2 inhibitor, Epadostat a IDO1 inhibitor (like BMS's). Melanoma shows both IDO1 and IDO2 overexpression, whereas Pancreatic Cancer and AML have a significant IDO2 overexpression. IDO2 overxpression is high in some tumor types, for which Indoximod will have no or little competition: two of them are Pancreatic Cancer and AML, but
also gastric and colon cancers
http://www.sciencedirect.com/science/article/pii/S2452336417300201
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3176891/
http://www.bloodjournal.org/content/126/23/1191?sso-checked=true
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM